A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: Subset analysis of Japanese patients

International Journal of Clinical Oncology

Volumn 18, Issue 4, 2013, Pages 621-628

  Iwata, Hiroji ^a   Narabayashi, Masaru ^b   Ito, Yoshinori ^c   Saji, Shigehira ^d,g   Fujiwara, Yasuhiro ^e   Usami, Shigeyuki ^f   Katsura, Koichi ^f   Sasaki, Yasutsuna ^g  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^c CANCER CHEMOTHERAPY CENTER   (Japan)

^d TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

^f Development and Medical Affairs Division   (Japan)

^g SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Brain metastases; HER2; Lapatinib; Metastatic breast cancer; Tyrosine kinase inhibitor

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TRASTUZUMAB;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BILIRUBIN BLOOD LEVEL; BRAIN METASTASIS; BRAIN SIZE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRY SKIN; FEMALE; HEMOGLOBIN BLOOD LEVEL; HER2 OVEREXPRESSING METASTATIC BREAST CANCER; HOT FLUSH; HUMAN; JAPANESE; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; METASTASIS POTENTIAL; MONOTHERAPY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; STOMATITIS; SYSTEMIC THERAPY; TUMOR VOLUME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BRAIN NEOPLASMS; BREAST NEOPLASMS; CRANIAL IRRADIATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; QUINAZOLINES; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84882632750     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-012-0444-2     Document Type: Article

References (21)

1. Burstein HJ, Lieberman G, Slamon DJ et al (2005) Isolated central nervous system metastases in patients with HER2-overexpressing advance breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 16:1772-1777
2. Pestalozzi BC, Zahrieh D, Price KN et al (2006) Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 17:935-944
3. Bendell JC, Domchek SM, Burstein HJ et al (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer (Phila) 97:2972-2977
4. Clayton AJ, Danson S, Jolly S et al (2004) Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91:639-643
5. Lin NU, Winer EP (2007) Brain metastases: the HER2 paradigm. Clin Cancer Res 13:1648-1655
6. Stemmler HJ, Kahlert S, Siekiera W et al (2006) Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 15:219-225
7. Yau T, Swanton C, Chua S et al (2006) Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 45:196-201
8. Toyama T (2009) 7. Lapatinib and brain metastasis, clinical and experimental aspects of breast cancer. In: Toi M (ed) Iyaku (Medicine and Drug). Journal Co., Tokyo, p 877
9. Bezjak A, Adam J, Barton R et al (2002) Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer 38:487-496
10. Arslan C, Dizdar O, Altundag K (2010) Systemic treatment in breast-cancer patients with brain metastasis. Expert Opin Pharmacother 11:1089-1100
11. Rusnak DW, Lackey K, Affleck K et al (2001) The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1:85-94
12. Gril B, Palmieri D, Bronder JL et al (2008) Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 100:1092-1103
13. Lin NU, Carey LA, Liu MC et al (2008) Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26:1993-1999
14. Lin NU, Dieras V, Paul D et al (2009) Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15:1452-1459
15. Nakagawa K, Minami H, Kanezaki M et al (2009) Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumors. Jpn J Clin Oncol 39:116-123
16. Toi M, Iwata H, Fujiwara Y et al (2009) Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. Br J Cancer 101:1676-1682
17. Burstein HJ, Storniolo AM, Franco S et al (2008) A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 19:1068-1074
18. Blackwell KL, Pegram MD, Tan-Chiu E et al (2009) Single-agent lapatinib for the treatment of HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab containing regimens. Ann Oncol 20:1026-1031
19. Burris HA III, Hurwitz HI, Dees EC et al (2005) Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23:5305-5313
20. Burris HA III, Taylor CW, Jones SF et al (2009) A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin Cancer Res 15:6702-6708
21. Stemmler HJ, Schmitt M, Willems A et al (2007) Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 18:23-28